Several survival markers for GBM have been identified so far, such as the patients’ age, initial clinical condition, extent of resection (EOR) and, particularly, molecular tumor characteristics such as methylation of the O6-methylguanin-DNA-methyltransferase (MGMT) gene promotor, or mutation of the isocitrate-dehydrogenase 1 (IDH1) gene [5]. The gene discussed is MGMT; the disease is glioblastoma.